Synthesis of new 4,4-spirocycloalkenic 1,2-diphenylpyrazolidine-3,5-dione derivatives by ring-closing metathesis reactions

Authors

  • V. M. Holovatiuk Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine, Ukraine
  • Yu. V. Bezugly Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine, Ukraine
  • V. I. Kashkovsky Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine, Ukraine

DOI:

https://doi.org/10.24959/ophcj.14.803

Keywords:

ruthenium carbene catalysts, metathesis reactions, ring-closing methathesis (RCM), pyrazolidine- 3, 5-diones, 1, 2-diazolidines, biological activity

Abstract

The present article describes the synthesis of new 4,4-spiroalkenic 1,2-diarylpyrazolidine-3,5-diones by ring-closing metathesis reactions (RCM). They may be potential biological active compounds since a great quantity of 1,2-diazoles show a wide spectrum of both biological and pharmacological activities, and therefore, they are successfully used in biology, medicine, veterinary medicine. The initial compounds for ring closing metathesis cyclization were synthesized by the corresponding hydrazobenzenes condensation with various allylmalonic acid derivatives, whereupon monoallylpyrazolidinediones obtained were alkylated by some halogenoalkenes to form unsaturated disubstituted 1,2-diarylpyrazolidine-3,5-dione with subsequent ring-closing metathesis. The most appropriate catalyst for carrying out the aforementioned conversion appeared to be the ruthenium carbene Grubbs complex of the second generation used in the concentration not more than 3 mol.%. The yield of the metathesis products was 75-91%. The preliminary computer prognosis of the biological activity of the new spirocycloalkenic 1,2-diazoles by means of Prediction of Activity Spectra for Substances programme has shown that the substances obtained with the high probability may be inhibitors of L-glutamate oxidase and testosterone 17-beta-dehydrogenase (NADP+), nicotine 2alpha2beta receptor antagonists, as well as they can have the anti-inflammatory properties.

Downloads

Download data is not yet available.

References

<p>1. Rubtsov M. V., Baichikov A. G. Sinteticheskie khimiko-farmatsevticheskie preparaty (The synthetic chemical and pharmaceutical preparations). Moscow, 1971, p.162.</p><p>2. Tamotsu Koyama, Yoshihiro Izawa, Hiroshi Wada, Tokutaro Makita, Yoshinobu Hashimoto, Makoto Enomoto. Toxicological aspects of feprazone, a new nonsteroidal anti-inflammatory drug. Toxicology and applied pharmacology, 1982, 64 (2), pp.255-270.</p><p>3. Cited 2 times. doi: 10.1016/0041-008X(82)90222-8</p><p>4. William Fraser, Colin J. Suckling and Hamish C. S. Wood. Latent inhibitors. Part 7. Inhibition of dihydro-orotate dehydrogenase by spirocyclopropanobarbiturates. Journal of the Chemical Society, 1990, Perkin Transactions 1, No.11, рp.3137-3144.</p><p>5. Cited 23 times. doi: 10.1039/P19900003137</p><p>6. Kumar and Jain. Synthesis and antimicrobial evaluation of 4-benzylidene-pyrazolidine-3,5-dione derivatives. International Journal of Pharmaceutical Sciences and Research, 2013, Vol. 4, issue 1, pp.453-457.</p><p>7. Filimonov D. A., Poroykov V. V. Rossiyskiy khimicheskiy jurnal – Russian chemical journal, 2006, No.2, pp.66-75.</p><p>8. Chang-Rui Zhanga, Yu-Lu Wang. A Simple and Efficient Method for the Reduction of Azo Compounds. Synthetic Communications, 2003, Vol. 33, No.24, рр.4205-4208.</p><p>9. Cited 1times. doi: 10.1081/SCC-120026848</p><p>10. Michel K., Matter M. Synthese von Pyrano[2,3-c]pyrazol-3-onen Über Pyrazole. Helvetica Chimica Acta, 1961, No.22, pp.1025-1030.</p><p>11. Cited 3 times. doi: 10.1002/hlca.19610440420</p><p>12. Holovatiuk V. M., Bezugly Yu. V., Kashkovsky V. I. Dopovidi natsionalnoi akademii nauk Ukrainy – Reports of the National Academy of Sciences of Ukraine, 2011, No.12, pp.118-124.</p>

Downloads

Published

2014-09-12

How to Cite

(1)
Holovatiuk, V. M.; Bezugly, Y. V.; Kashkovsky, V. I. Synthesis of New 4,4-Spirocycloalkenic 1,2-Diphenylpyrazolidine-3,5-Dione Derivatives by Ring-Closing Metathesis Reactions. J. Org. Pharm. Chem. 2014, 12, 33-37.

Issue

Vol. 12 No. 3(47) (2014)

Section

Original Researches

License

Copyright (c) 2014 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:

1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.

3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).